Spranger, Joachim <br/><br/>
GLP-1-based therapies: the dilemma of uncertainty.  [electronic resource] 

 -  Gastroenterology  Jul 2011 
 - 20-3 p.  digital 
<br/><br/> Publication Type: Editorial; Comment 
<br/><br/><label>ISSN: </label>1528-0012 
<br/><br/><label>Standard No.: </label>10.1053/j.gastro.2011.05.019  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Diabetes Mellitus, Type 2--drug therapy<br/>Dipeptidyl-Peptidase IV Inhibitors--adverse effects<br/>Exenatide<br/>Glucagon-Like Peptide-1 Receptor<br/>Humans<br/>Hypoglycemic Agents--adverse effects<br/>Pancreatic Neoplasms--chemically induced<br/>Pancreatitis--chemically induced<br/>Peptides--adverse effects<br/>Pyrazines--adverse effects<br/>Receptors, Glucagon--agonists<br/>Risk Assessment<br/>Risk Factors<br/>Sitagliptin Phosphate<br/>Thyroid Neoplasms--chemically induced<br/>Triazoles--adverse effects<br/>Uncertainty<br/>Venoms--adverse effects